查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933312

非何杰金氏淋巴瘤治疗市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察，预测（2026-2034 年）

Non-Hodgkin Lymphoma Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 125 Pages | 商品交期: 请询问到货日

价格

非何杰金氏淋巴瘤 (NHL) 治疗市场成长驱动因子

预计未来十年，全球非何杰金氏淋巴瘤 (NHL) 治疗市场将稳定成长。该市场预计在 2025 年达到 115.9 亿美元，2026 年增至 125.7 亿美元，并在 2034 年达到 194.4 亿美元。这意味着 2026 年至 2034 年的复合年增长率 (CAGR) 为 6.25%。北美地区在 2025 年将占市场主导地位，市场占有率达到 49.35%，这主要得益于 NHL 的高发病率、先进疗法的引入以及完善的医疗保健基础设施。

非何杰金氏淋巴瘤是全​​球最常见的淋巴瘤和癌症类型。这些恶性肿瘤若不及时治疗可能致命。目前正在进行多项临床试验，旨在开发復发性和难治性非何杰金氏淋巴瘤的治疗方法，这表明人们对有效疗法的兴趣日益浓厚。

市场驱动因素

非何杰金氏淋巴瘤治疗市场的主要驱动因素是其高发生率和侵袭性。许多类型的非何杰金氏淋巴瘤在晚期之前都没有症状，因此早期诊断和标靶治疗至关重要。临床疗效的改善和治癒率的提高进一步推动了先进疗法的应用，特别是免疫疗法和标靶疗法。

例如，免疫疗法正逐渐成为一种创新且先进的治疗方法，它透过标靶机制来提高患者的存活率。 Kite Pharma/Gilead Sciences 的 Yescarta 等产品正在显着推动该领域的成长。

此外，对復发或难治性非何杰金氏淋巴瘤 (NHL) 有效治疗的需求正在推动先进疗法的研发和应用，从而促进市场成长。

市场限制因子

儘管市场成长，但由于先进疗法的高昂成本，尤其是在新兴国家，市场仍面临挑战。免疫疗法和 CAR-T 细胞疗法的高昂成本限制了许多患者的治疗机会。政府报销限制和缺乏专门的支付机制进一步阻碍了发展中地区的市场扩张。

市场趋势

主要市场趋势包括研发投入的增加和先进疗法的上市。在对晚期和復发性 NHL 创新疗法的需求推动下，领先企业正专注于研发管线。先进的诊断技术和早期检测改善了患者的治疗效果，进一步推动了先进疗法的应用。

此外，人们对 CAR-T 细胞疗法和个人化医疗的兴趣日益浓厚，这反映出治疗方式正从传统化疗转向更精准、更具标靶性的免疫疗法。

市场区隔分析

依疗法分类：

  • 预计到 2026 年，免疫疗法将占 57.45% 的市场占有率，并在 2025 年创造 66.4 亿美元的收入，这主要得益于 Yescarta 等疗法的推广。
  • 标靶疗法因其精准性和疗效而占了可观的收入。
  • 化疗仍然是标准疗法，但由于仿製药的广泛应用，其收入贡献正在下降。
  • 其他疗法包括使用皮质类固醇作为辅助治疗。

依疾病类型划分：

  • 到2026年，B细胞淋巴瘤将占87.04%的市场占有率，反映出其发生率高于T细胞淋巴瘤。
  • T细胞淋巴瘤是一种相对罕见的疾病，对市场的贡献有限。

依分销管道划分：

  • 到2026年，医院药局将占60.16%的市场占有率，因为大多数治疗需要由训练有素的专业人员进行静脉注射。
  • 由于口服製剂有限，零售药局的成长将较为缓慢。
  • 由于便利性和处方服务的日益普及，线上药局正在兴起。

依地区分析

北美：预计2025年市场规模将达57.2亿美元，2026年将达58亿美元。这主要得益于人们对先进疗法的认知度高、渗透率高以及应用广泛。

欧洲：预计欧洲市场将以8.0%的复合年增长率显着成长，其中英国市场规模到2026年将达到5.5亿美元，德国市场规模将达到8.1亿美元。 CAR-T细胞疗法等新型疗法将推动市场扩张。

亚太地区：由于监管部门的批准和庞大的患者群体，预计亚太地区市场将快速成长。 预计到2025年，日本市场规模将达到9.009亿美元，到2026年将达到9.9亿美元；中国市场规模预计将达到7.3亿美元；印度市场规模预计将达到3.4亿美元。

世界其他地区：拉丁美洲和中东/非洲等新兴市场由于医疗保健支出和意识的提高，预计对先进疗法的需求将不断增长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇

第四章：关键考虑因素

  • 2025年主要国家淋巴瘤盛行率
  • 在开发产品分析
  • 主要行业趋势
  • 主要地区的监管环境
  • 非何杰金氏淋巴瘤经济负担分析
  • 新产品上市
  • 非何杰金氏淋巴瘤新兴疗法概述淋巴瘤

第五章：全球非何杰金氏淋巴瘤治疗市场分析、洞察与预测（2021-2034）

  • 主要发现/摘要
  • 市场分析、洞察与预测 - 依疗法分类
    • 免疫疗法
    • 标靶疗法
    • 化疗
    • 其他
  • 市场分析、洞察与预测 - 依疾病类型分类
    • B细胞淋巴瘤
    • T细胞淋巴瘤
  • 市场分析、洞察与预测 - 依销售管道分类
    • 医院药房
    • 零售药局和药局
    • 线上药房
  • 市场分析、洞察与预测 - 依区域
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美非何杰金氏淋巴瘤治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲非何杰金氏淋巴瘤治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚半岛
    • 其他地区欧洲

第八章 亚太地区非何杰金氏淋巴瘤治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲非何杰金氏淋巴瘤治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章 中东与非洲非何杰金氏淋巴瘤治疗市场分析洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会国家
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 主要行业趋势
  • 全球市占率分析（2025）
  • 竞争格局概览
  • 主要公司比较分析
  • 公司简介
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca
  • Bayer AG
  • Novartis AG
  • Spectrum Pharmaceuticals, Inc.
  • Bristol Myers Squibb Company
  • Janssen Pharmaceuticals, Inc.
  • Genentech, Inc.(F． Hoffmann-La Roche Ltd)
  • Merck &Co., Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Other Prominent Players

第十二章：策略建议

Product Code: FBI102642

Growth Factors of non-Hodgkin lymphoma (NHL) treatment Market

The global non-Hodgkin lymphoma (NHL) treatment market is projected to grow steadily over the next decade. In 2025, the market was valued at USD 11.59 billion, expected to rise to USD 12.57 billion in 2026 and reach USD 19.44 billion by 2034, reflecting a CAGR of 6.25% from 2026-2034. North America dominated the market with a 49.35% share in 2025, driven by the high prevalence of NHL, adoption of advanced therapies, and robust healthcare infrastructure.

Non-Hodgkin lymphomas are among the most common forms of lymphomas and cancers globally. These malignancies, if left untreated, can be potentially lethal. Several clinical trials are ongoing to develop therapies for relapsed and refractory NHL, indicating growing interest in effective treatments.

Market Drivers

The NHL treatment market is primarily driven by high prevalence and aggressive nature of non-Hodgkin lymphomas. Many NHL types remain asymptomatic until advanced stages, necessitating early diagnosis and targeted therapies. Improved clinical outcomes and strong cure rates further drive the adoption of advanced therapeutics, particularly immunotherapies and targeted therapies.

Immunotherapy, for instance, has emerged as a novel and sophisticated therapeutic approach, offering targeted mechanisms that improve survival outcomes. Products like Yescarta by Kite Pharma/Gilead Sciences have contributed significantly to the segment's growth.

Additionally, the need for effective treatments for relapsed or refractory NHL cases has encouraged development and adoption of advanced therapies, boosting market growth.

Market Restraints

Despite growth, the market faces challenges from the high costs of advanced therapies, especially in emerging countries. Immunotherapies and CAR-T cell therapies are expensive, restricting access for a large portion of patients. Limited government reimbursement and absence of specialized payment schemes further restrain market expansion in developing regions.

Market Trends

Key market trends include increased R&D investments and launch of advanced therapeutics. Major companies are focusing on pipeline development, driven by the need for innovative therapies in aggressive and relapsed NHL cases. Sophisticated diagnostic techniques and early detection improve patient prognosis, which further promotes adoption of advanced treatment options.

Moreover, there is a growing interest in CAR-T cell therapies and personalized medicine approaches, reflecting a shift from conventional chemotherapy toward more precise, targeted, and immunotherapy-based interventions.

Segmentation Analysis

By Therapy Type:

  • Immunotherapy dominates with 57.45% share in 2026, generating USD 6.64 billion in 2025, supported by therapies like Yescarta.
  • Targeted therapies hold significant revenue due to precision and efficacy.
  • Chemotherapy remains standard treatment but contributes lower revenue due to generics.
  • Others include corticosteroids as supportive treatments.

By Disease Type:

  • B-cell lymphoma accounts for 87.04% of the market in 2026, reflecting its higher prevalence compared to T-cell lymphoma.
  • T-cell lymphoma remains comparatively rare, limiting its market contribution.

By Distribution Channel:

  • Hospital pharmacies dominate with 60.16% share in 2026, as most therapies require intravenous administration by trained professionals.
  • Retail pharmacies show moderate growth due to limited oral formulations.
  • Online pharmacies are emerging, driven by convenience and growing adoption of prescription services.

Regional Analysis

North America: Market size USD 5.72 billion in 2025, projected to reach USD 5.8 billion by 2026, driven by high awareness, prevalence, and adoption of advanced therapies.

Europe: Significant growth expected with CAGR of 8.0%, UK market USD 0.55 billion and Germany USD 0.81 billion by 2026. New therapeutics like CAR-T cell therapies support market expansion.

Asia-Pacific: Rapid growth anticipated due to regulatory approvals and large patient base. Japan market USD 900.9 million in 2025, projected USD 0.99 billion by 2026, China USD 0.73 billion, India USD 0.34 billion by 2026.

Rest of World: Latin America and Middle East & Africa are nascent markets but increasing healthcare expenditure and awareness is expected to drive demand for advanced therapies.

Competitive Landscape

The NHL treatment market is highly competitive. Key players include Novartis AG, Gilead Sciences/Kite Pharma, Takeda, AstraZeneca, Bayer AG, Bristol Myers Squibb, Genentech, among others. Companies focus on advanced therapies such as immunotherapy, CAR-T, and targeted therapies. Emerging players like Spectrum Pharmaceuticals are expanding market presence through innovative therapeutics and pipeline development.

Recent Developments:

  • Feb 2021: Bristol Myers Squibb received FDA approval for CAR-T therapy Breyanzi for relapsed/refractory large B-cell lymphoma.
  • Dec 2020: AstraZeneca's Calquence showed positive Phase 2 results for mantle cell lymphoma.
  • June 2020: Kyowa Kirin launched POTELIGO for rare lymphomas in Germany.

Conclusion

The global non-Hodgkin lymphoma treatment market is projected to grow from USD 11.59 billion in 2025 to USD 19.44 billion by 2034, at a CAGR of 6.25%. Market growth is driven by the high prevalence of NHL, need for targeted therapies, rising adoption of immunotherapies, and ongoing R&D. While high therapy costs and limited access in emerging countries present challenges, expanding clinical pipelines, regulatory approvals, and increasing awareness are expected to sustain market growth across North America, Europe, and Asia-Pacific.

Segmentation By Therapy

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Others

By Disease Type

  • B-cell Lymphoma
  • T-cell Lymphoma

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia-Pacific)
  • Latin America (Brazil, Mexico, and the Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and the Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Lymphoma - by Key Countries - 2025
  • 4.2. Pipeline Analysis
  • 4.3. Key Industry Developments
  • 4.4. Regulatory Scenario, by Key Regions
  • 4.5. Analysis of Economic Burden of Non-Hodgkin Lymphoma
  • 4.6. New Product Launches
  • 4.7. Overview of Emerging Treatments for Non-Hodgkin Lymphoma

5. Global Non-Hodgkin Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Therapy
    • 5.2.1. Immunotherapy
    • 5.2.2. Targeted Therapy
    • 5.2.3. Chemotherapy
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Disease Type
    • 5.3.1. B-cell Lymphoma
    • 5.3.2. T-cell Lymphoma
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies & Drug Stores
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Non-Hodgkin Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Therapy
    • 6.2.1. Immunotherapy
    • 6.2.2. Targeted Therapy
    • 6.2.3. Chemotherapy
    • 6.2.4. Others
  • 6.3. Market Analysis - By Disease Type
    • 6.3.1. B-cell Lymphoma
    • 6.3.2. T-cell Lymphoma
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies & Drug Stores
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Non-Hodgkin Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Therapy
    • 7.2.1. Immunotherapy
    • 7.2.2. Targeted Therapy
    • 7.2.3. Chemotherapy
    • 7.2.4. Others
  • 7.3. Market Analysis - By Disease Type
    • 7.3.1. B-cell Lymphoma
    • 7.3.2. T-cell Lymphoma
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies & Drug Stores
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis - By Country/ sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Non-Hodgkin Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Therapy
    • 8.2.1. Immunotherapy
    • 8.2.2. Targeted Therapy
    • 8.2.3. Chemotherapy
    • 8.2.4. Others
  • 8.3. Market Analysis - By Disease Type
    • 8.3.1. B-cell Lymphoma
    • 8.3.2. T-cell Lymphoma
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies & Drug Stores
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis - By Country/ sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Non-Hodgkin Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Therapy
    • 9.2.1. Immunotherapy
    • 9.2.2. Targeted Therapy
    • 9.2.3. Chemotherapy
    • 9.2.4. Others
  • 9.3. Market Analysis - By Disease Type
    • 9.3.1. B-cell Lymphoma
    • 9.3.2. T-cell Lymphoma
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies & Drug Stores
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis - By Country/ sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Therapy
    • 10.2.1. Immunotherapy
    • 10.2.2. Targeted Therapy
    • 10.2.3. Chemotherapy
    • 10.2.4. Others
  • 10.3. Market Analysis - By Disease Type
    • 10.3.1. B-cell Lymphoma
    • 10.3.2. T-cell Lymphoma
  • 10.4. Market Analysis - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies & Drug Stores
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis - By Country/ sub-region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.5.1. Takeda Pharmaceutical Company Limited
      • 11.5.1.1. Overview,
      • 11.5.1.2. Products & services,
      • 11.5.1.3. SWOT analysis,
      • 11.5.1.4. Recent developments,
      • 11.5.1.5. strategies,
      • 11.5.1.6. financials (based on availability)
    • 11.5.2. AstraZeneca
      • 11.5.2.1. Overview,
      • 11.5.2.2. Products & services,
      • 11.5.2.3. SWOT analysis,
      • 11.5.2.4. Recent developments,
      • 11.5.2.5. strategies,
      • 11.5.2.6. financials (based on availability)
    • 11.5.3. Bayer AG
      • 11.5.3.1. Overview,
      • 11.5.3.2. Products & services,
      • 11.5.3.3. SWOT analysis,
      • 11.5.3.4. Recent developments,
      • 11.5.3.5. strategies,
      • 11.5.3.6. financials (based on availability)
    • 11.5.4. Novartis AG
      • 11.5.4.1. Overview,
      • 11.5.4.2. Products & services,
      • 11.5.4.3. SWOT analysis,
      • 11.5.4.4. Recent developments,
      • 11.5.4.5. strategies,
      • 11.5.4.6. financials (based on availability)
    • 11.5.5. Spectrum Pharmaceuticals, Inc.
      • 11.5.5.1. Overview,
      • 11.5.5.2. Products & services,
      • 11.5.5.3. SWOT analysis,
      • 11.5.5.4. Recent developments,
      • 11.5.5.5. strategies,
      • 11.5.5.6. financials (based on availability)
    • 11.5.6. Bristol Myers Squibb Company
      • 11.5.6.1. Overview,
      • 11.5.6.2. Products & services,
      • 11.5.6.3. SWOT analysis,
      • 11.5.6.4. Recent developments,
      • 11.5.6.5. strategies,
      • 11.5.6.6. financials (based on availability)
    • 11.5.7. Janssen Pharmaceuticals, Inc.
      • 11.5.7.1. Overview,
      • 11.5.7.2. Products & services,
      • 11.5.7.3. SWOT analysis,
      • 11.5.7.4. Recent developments,
      • 11.5.7.5. strategies,
      • 11.5.7.6. financials (based on availability)
    • 11.5.8. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
      • 11.5.8.1. Overview,
      • 11.5.8.2. Products & services,
      • 11.5.8.3. SWOT analysis,
      • 11.5.8.4. Recent developments,
      • 11.5.8.5. strategies,
      • 11.5.8.6. financials (based on availability)
    • 11.5.9. Merck & Co., Inc.
      • 11.5.9.1. Overview,
      • 11.5.9.2. Products & services,
      • 11.5.9.3. SWOT analysis,
      • 11.5.9.4. Recent developments,
      • 11.5.9.5. strategies,
      • 11.5.9.6. financials (based on availability)
    • 11.5.10. Spectrum Pharmaceuticals, Inc.
      • 11.5.10.1. Overview,
      • 11.5.10.2. Products & services,
      • 11.5.10.3. SWOT analysis,
      • 11.5.10.4. Recent developments,
      • 11.5.10.5. strategies,
      • 11.5.10.6. financials (based on availability)
    • 11.5.11. Other Prominent Players
      • 11.5.11.1. Overview,
      • 11.5.11.2. Products & services,
      • 11.5.11.3. SWOT analysis,
      • 11.5.11.4. Recent developments,
      • 11.5.11.5. strategies,
      • 11.5.11.6. financials (based on availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Therapy, 2015-2034
  • Table 2: Global Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2015-2034
  • Table 3: Global Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2015-2034
  • Table 4: Global Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 6: North America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 7: North America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 10: Europe Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 11: Europe Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 14: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 15: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 18: Latin America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 19: Latin America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Therapy, 2021-2034
  • Table 22: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Disease Type, 2021-2034
  • Table 23: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Non-Hodgkin Lymphoma Treatment Market Revenue Breakdown (US$ Mn, %) by Region, 2025 & 2034
  • Figure 2: Global Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 3: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Immunotherapy, 2021-2034
  • Figure 4: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Targeted Therapy, 2021-2034
  • Figure 5: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Chemotherapy, 2021-2034
  • Figure 6: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 7: Global Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Disease Type, 2025 & 2034
  • Figure 8: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by B-cell Lymphoma, 2021-2034
  • Figure 9: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by T-cell Lymphoma, 2021-2034
  • Figure 10: Global Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 11: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Hospital Pharmacies, 2021-2034
  • Figure 12: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Retail Pharmacies & Drug Stores, 2021-2034
  • Figure 13: Global Non-Hodgkin Lymphoma Treatment Market Forecast (US$ Mn), by Online Pharmacies, 2021-2034
  • Figure 14: Global Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Region, 2025 & 2034
  • Figure 15: North America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 16: North America Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Therapy, 2025
  • Figure 17: North America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 18: North America Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 19: North America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 20: North America Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: North America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), By Country, 2025 & 2034
  • Figure 22: North America Non-Hodgkin Lymphoma Treatment Market Value Share (%), By Country, 2025
  • Figure 23: Europe Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 24: Europe Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Therapy, 2025
  • Figure 25: Europe Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 26: Europe Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 27: Europe Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 28: Europe Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 29: Europe Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 30: Europe Non-Hodgkin Lymphoma Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 31: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 32: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Therapy, 2025
  • Figure 33: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 34: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 35: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 36: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 37: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 38: Asia Pacific Non-Hodgkin Lymphoma Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 39: Latin America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 40: Latin America Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Therapy, 2025
  • Figure 41: Latin America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 42: Latin America Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 43: Latin America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Non-Hodgkin Lymphoma Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Therapy, 2025 & 2034
  • Figure 48: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Therapy, 2025
  • Figure 49: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Disease Type, 2025 & 2034
  • Figure 50: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Disease Type, 2025
  • Figure 51: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), by Distribution Channel, 2025 & 2034
  • Figure 52: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 53: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value (US$ Mn), By Country/ Sub-region, 2025 & 2034
  • Figure 54: Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 55: Global Non-Hodgkin Lymphoma Treatment Market Share (%), By Company, 2025